Nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: An economic analysis of a prospective randomized trial

George Dranitsaris*, Robert Coleman, William Gradishar

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Fingerprint

Dive into the research topics of 'Nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: An economic analysis of a prospective randomized trial'. Together they form a unique fingerprint.

INIS

Pharmacology, Toxicology and Pharmaceutical Science